vasopressin receptor

vasopressin receptor
Name	Vasopressin receptor

vasopressin receptor

The vasopressin receptor family comprises G protein–coupled receptors that bind the peptide hormone arginine vasopressin and mediate diverse effects on water balance, vascular tone, social behavior, and stress responses. In mammals the receptors exhibit distinct tissue distributions and coupling preferences, integrating signals from neuroendocrine centers such as the hypothalamus and pituitary with peripheral effectors including the kidney, heart, and vasculature. Studies across physiology, pharmacology, and clinical medicine have connected receptor variants to disorders studied by investigators at institutions like Harvard University, University of Cambridge, and National Institutes of Health.

Structure and subtypes

The receptor family includes several subtypes encoded by genes identified through genomic projects at Human Genome Project consortium centers and characterized biochemically at laboratories affiliated with Max Planck Society and Cold Spring Harbor Laboratory. Subtypes commonly classified in mammals are V1A, V1B (also V3), and V2, each encoded on separate loci discovered by molecular cloning teams at institutions such as Stanford University and Massachusetts Institute of Technology. These receptors share the canonical seven-transmembrane topology first described in seminal work by researchers associated with Nobel Prize–winning laboratories and display conserved motifs revealed by structural biology studies at facilities like European Molecular Biology Laboratory and Protein Data Bank repositories. High-resolution models derived from cryo-electron microscopy and X-ray crystallography projects at Royal Society and Max Planck Institute centers have illustrated differences in extracellular loops and intracellular C-terminal tails that govern subtype-specific interactions with intracellular partners identified in proteomics efforts at Broad Institute.

Signaling mechanisms

V1A and V1B subtypes primarily couple to Gq/11 proteins, activating phospholipase C pathways delineated in signaling studies at Cold Spring Harbor Laboratory and Salk Institute for Biological Studies, leading to inositol trisphosphate production and intracellular calcium mobilization reported in experiments from Johns Hopkins University and University of Oxford. V2 receptors preferentially couple to Gs proteins to stimulate adenylyl cyclase and cyclic AMP generation, a pathway characterized in classic endocrine research at Yale University and Columbia University. Receptor phosphorylation by kinases mapped by researchers at National Cancer Institute and European Bioinformatics Institute promotes arrestin recruitment and receptor internalization, processes elucidated in studies associated with Institut Pasteur and UCSF Medical Center. Cross-talk with mitogen-activated protein kinase cascades has been observed in projects at Pennsylvania State University and University of California, San Diego, linking receptor activation to transcriptional responses identified in laboratories at University of Chicago.

Physiological roles

V1A receptors regulate vascular smooth muscle contractility and are implicated in blood pressure control studied by cardiovascular groups at Cleveland Clinic and Mayo Clinic, as well as in hepatic glycogenolysis described by metabolic researchers at Imperial College London. V1B receptors are concentrated in pituitary corticotrophs where they modulate adrenocorticotropic hormone release during stress responses investigated by teams at Columbia University Irving Medical Center and University College London. V2 receptors in renal collecting ducts control aquaporin-2 trafficking and urine concentration, a mechanism characterized in nephrology programs at Karolinska Institute and University of Toronto. Beyond classical roles, vasopressin receptor signaling influences social cognition and pair-bonding behaviors explored in behavioral studies at Princeton University, Rutgers University, and field research connected to Smithsonian Institution collections. Ontogenetic expression patterns have been mapped in developmental biology efforts at University of California, Berkeley and Duke University.

Pharmacology and ligands

Endogenous ligand arginine vasopressin was first isolated and sequenced in biochemical programs associated with University of Basel and University of Vienna, and its analogs and antagonists have been developed by pharmaceutical groups at Pfizer, Novartis, and GlaxoSmithKline. Selective V2 agonists such as desmopressin are used clinically following trials coordinated by centers like Cleveland Clinic Foundation and Mayo Clinic Arizona, whereas nonpeptide V1A and V2 antagonists were advanced in drug discovery pipelines at Merck & Co. and AstraZeneca. Ligand–receptor binding kinetics and structure–activity relationships have been characterized using biophysical platforms at European Molecular Biology Laboratory and Lawrence Berkeley National Laboratory, while high-throughput screening performed at Broad Institute and GlaxoSmithKline uncovered subtype-selective modulators. Pet imaging ligands for receptor visualization in vivo were developed in collaborations involving National Institutes of Health and imaging centers at Massachusetts General Hospital.

Clinical significance and disorders

Mutations and polymorphisms in receptor genes have been associated with nephrogenic diabetes insipidus and hyponatremia documented in case series from Johns Hopkins Hospital and genetic studies at National Human Genome Research Institute. Dysregulation of V1A/V1B signaling has been implicated in psychiatric disorders such as autism spectrum disorder and major depressive disorder studied at McLean Hospital and King's College London psychiatric research units. Cardiovascular implications include heart failure and portal hypertension where antagonist therapy has been trialed at Mount Sinai Hospital and multicenter consortia coordinated by European Society of Cardiology. Endocrine oncology interactions, such as ectopic vasopressin secretion in small cell lung carcinoma, have been reported from oncology centers including Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Research methods and models

Experimental approaches span molecular cloning and mutagenesis pioneered at institutions like Cold Spring Harbor Laboratory and Sanger Institute, to transgenic animal models generated at facilities such as Jackson Laboratory and Max Delbrück Center for Molecular Medicine. In vitro assays employing cultured cell lines from repositories like ATCC and organoids developed in labs at Hubrecht Institute enable functional pharmacology screens conducted at Broad Institute and GlaxoSmithKline. Imaging of receptor trafficking and signaling uses microscopy platforms at Howard Hughes Medical Institute and Wellcome Trust–funded centers, while clinical trials registered through networks at World Health Organization and European Medicines Agency evaluate therapeutic candidates. Computational modeling and bioinformatics analyses performed by groups at European Bioinformatics Institute and Stanford University integrate structural data from Protein Data Bank and sequence variation catalogs from Ensembl to guide precision medicine initiatives.

Category:Receptors